A Conversation With California’s New Attorney General
By Jill Cowan,
New York Times
| 04. 28. 2021
On Friday, the former state lawmaker Rob Bonta officially became California’s attorney general, stepping into a role that has served as a launching pad for some of the state’s most powerful politicians.
Mr. Bonta was the last of three high-profile appointments by Gov. Gavin Newsom in what observers have described as the most significant reshuffling of Democratic power the state has experienced in years. That Mr. Newsom now has close allies in three of the state’s top posts is likely to pay dividends as he campaigns to keep his job in a recall election later this year.
But political calculus aside, the attorney general wields broad power to shape the state’s criminal justice agenda — a task that has taken on heightened urgency amid a reckoning over racism and police violence.
During his second full day on the job, I spoke with Mr. Bonta about his priorities. Our conversation has been edited and condensed.
Yesterday your office announced that you would release more gun violence data to researchers and the public. What else is on the agenda in the...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...